TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02237482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trilogy cup

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trabecular metal cup (TM)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trabecular metal cup (TM)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZCA cup
Study: NCT00861991

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Perspective taking instruction
Description: Students were asked to take the perspective of their standardized patients during clinical skills examinations
Study: NCT01589913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICD-Forum
Description: The CBT based internet program ICD-Forum is designed to increase QoL, and decrease anxiety and depression in ICD-patients. The program includes a therapist moderated asynchronous discussion group and content focused modules following a six weeks schedule:~1. Introduction to participants and online system~2. Knowledge regarding ICDs~3. Strategies for behavior change~4. Psychological models for anxiety and depression~5. Strategies to cope with avoidance, anxiety and depression~6. Resume, evaluation, resolution of open questions, goal setting, good bye
Study: NCT01086540

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylprednisolone
Description: Methylprednisolone (or equivalent corticosteroid) administered intravenously 30 minutes prior to each study drug infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Methylprednisolone (or equivalent corticosteroid) administered intravenously 30 minutes prior to each study drug infusion.
Study: NCT02090790

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iv dexamethasone
Description: 2 ml 8 mg iv dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: femoral dexamethasone
Description: 2ml 8mg dexamethasone administration added 30 ml 0,5 % bupivacain

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: serum physiologic
Description: 2 ml iv serum physiologic
Study: NCT00084656

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: IV over 90 mins on day 1, wks 1,9,17,25,33,41,53 Dose: 3 mg/kg (Part I), 10 mg/kg (Part II)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tyrosinase/gp100/MART-1 Peptides
Description: (All subjects in Part I and HLA-A\*0201 positive subjects only in Part II): SC, day 1 of wks 1,3,5,7,9,11,17, 21,25,33,41,53 Dose: 1 mg peptide emulsified in 1 mL Montanide ISA 51 VG.)
Study: NCT02438813

Intervention type: DRUG
Intervention: Deoxycholic acid
Description: Deoxycholic acid (ATX-101) injection as the treatment of SMF as per standard of care in clinical practice.

Intervention type: PROCEDURE
Intervention: Surgical Procedures
Description: Surgical procedures for treatment of SMF as per standard of care in clinical practice.

Intervention type: PROCEDURE
Intervention: Laser Liposuction
Description: Laser Liposuction for the treatment of SMF as per standard of care in clinical practice..

Intervention type: DEVICE
Intervention: Energy Devices
Description: Energy Devices for the treatment of SMF as per standard of care in clinical practice.

Intervention type: OTHER
Intervention: Other Treatments
Description: Other treatments for SMF as per standard of care in clinical practice.
Study: NCT03968185

Intervention type: OTHER
Intervention: Interfascial infiltration
Description: Injection of L-bupivacaine (50 mg) and dexamethasone (4 mg) in the interfascial space under ultrasound guidance.~Patients were kept under surveillance for at least one hour before discharge.~Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6 h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief.

Intervention type: OTHER
Intervention: Standard medical treatment
Description: Standard medical treatment include acetaminophen, NSAIDs and muscle relaxant as first line pharmacological treatment and escalation to analgesics level II or morphine if required, as needed for low back pain, in agreement with national guidelines Route of administration (orally or iv) was let at the discretion of the attending emergency physician.~Patients were kept under surveillance for one hour before discharge. Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief.
Study: NCT03113604

Intervention type: OTHER
Intervention: Study on samples of tumor and peri-tumor tissues from patients with hepatocellular carcinoma
Description: Retrospective study of samples of tumor and peri-tumor tissues from patients with hepatocellular carcinoma (HCC): three groups of samples will be selected:~Group 1: Tumor and peri-tumor tissue samples from patients with non-treated sorafenib CHC (surgical resection or other) Group 2: Tumor and peri-tumor tissue samples from tumor and peritumor tissues of patients not responding to sorafenib treatment Group 3: samples from patients responding to treatment with sorafenib

Intervention type: OTHER
Intervention: Study on samples of tumor and peri-tumor tissues from patients with hepatocellular carcinoma
Description: Retrospective study of samples of tumor and peri-tumor tissues from patients with hepatocellular carcinoma (HCC): three groups of samples will be selected:~Group 1: Tumor and peri-tumor tissue samples from patients with non-treated sorafenib CHC (surgical resection or other) Group 2: Tumor and peri-tumor tissue samples from tumor and peritumor tissues of patients not responding to sorafenib treatment Group 3: samples from patients responding to treatment with sorafenib

Intervention type: OTHER
Intervention: Study on samples of tumor and peri-tumor tissues from patients with hepatocellular carcinoma
Description: Retrospective study of samples of tumor and peri-tumor tissues from patients with hepatocellular carcinoma (HCC): three groups of samples will be selected:~Group 1: Tumor and peri-tumor tissue samples from patients with non-treated sorafenib CHC (surgical resection or other) Group 2: Tumor and peri-tumor tissue samples from tumor and peritumor tissues of patients not responding to sorafenib treatment Group 3: samples from patients responding to treatment with sorafenib
Study: NCT01629472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VSLA + Gender dialogue groups
Description: Dialogue groups discussing household discussion making and gender norms facilitated by IRC.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VSLA + Gender dialogue groups
Description: Dialogue groups discussing household discussion making and gender norms facilitated by IRC.
Study: NCT02074813

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Inspiratory muscle training
Study: NCT03394690

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: green coffee
Description: 2 capsuls

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: 2 capsuls
Study: NCT01260545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA-18C3
Description: 2.5 mg/kg, 3.75 mg/kg IV (in the vein) on Day 1 of each 14 day cycle until the subject is no longer benefiting clinically or unacceptable toxicity occurs.
Study: NCT00409344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: A continuous infusion of dexmedetomidine will be started at a dose of 0.8mcg/kg/hr. This will continue for no longer than 24 hours. Four hours post extubation the study drug wii be discontinued using a standard tapering protocol: 0.6mcg/kg/hr for 4 hours then 0.4mcg/kg/hr for 4 hours, then 0.2 mcg/kg/hr for 4 hours and then 0.1mcg/kg/hr for 4 hours and then turned off.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline will be given as the placebo and will administered at 0.8mcg/kg/hr

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline will be given as the placebo and will administered at 0.8mcg/kg/hr
Study: NCT04598269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-1777
Description: ATI-1777 topical solution 2.0% w/w

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle topical solution containing no ATI-1777
Study: NCT03550404

Intervention type: BEHAVIORAL
Intervention: Seasons of Care App
Description: A web-based mobile application (app) called the Seasons of Care Elder Navigation Guide will assist elders, their families/caregivers, healthcare providers, outreach workers, and other community members in navigating healthcare and insurance systems. The app has the added advantage of being easy to update to respond to future changes in health care and insurance, and sustainable because it is not dependent on intensive training, developing, and retaining of individuals in professional navigation positions.

Intervention type: BEHAVIORAL
Intervention: Seasons of Care App
Description: A web-based mobile application (app) called the Seasons of Care Elder Navigation Guide will assist elders, their families/caregivers, healthcare providers, outreach workers, and other community members in navigating healthcare and insurance systems. The app has the added advantage of being easy to update to respond to future changes in health care and insurance, and sustainable because it is not dependent on intensive training, developing, and retaining of individuals in professional navigation positions.

Intervention type: BEHAVIORAL
Intervention: Seasons of Care App
Description: A web-based mobile application (app) called the Seasons of Care Elder Navigation Guide will assist elders, their families/caregivers, healthcare providers, outreach workers, and other community members in navigating healthcare and insurance systems. The app has the added advantage of being easy to update to respond to future changes in health care and insurance, and sustainable because it is not dependent on intensive training, developing, and retaining of individuals in professional navigation positions.
Study: NCT01027260

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itopride HCI 50 mg
Description: Variable dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itopride HCI 100 mg
Description: Variable dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Variable dosing
Study: NCT01175395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI-20089/Lucentis
Description: Combining a single dose of IBI-20089 (6.9 mg or 13.8 mg) intravitreal injection adjunctively with Lucentis 0.5 mg intravitreal injection at baseline and monthly intravitreal Lucentis injection PRN based on clinical and OCT results.
Study: NCT04400929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Dosage for IV Leukine® injection: 125mcg/m2/day over a 4-hour period for up to 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Dosage for IV Leukine® injection: 125mcg/m2/day over a 4-hour period for up to 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Dosage for IV Leukine® injection: 125mcg/m2/day over a 4-hour period for up to 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Dosage for IV Leukine® injection: 125mcg/m2/day over a 4-hour period for up to 5 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 0.9%
Description: IV normal saline 0.9% for 5 days
Study: NCT03869333

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Invaplex[AR-DETOX]
Description: Detoxified Shigella flexneri 2a Artificial Invasin Complex (Invaplex\[AR-Detox\]) Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Invaplex[AR-DETOX]
Description: Detoxified Shigella flexneri 2a Artificial Invasin Complex (Invaplex\[AR-Detox\]) Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Invaplex[AR-DETOX]
Description: Detoxified Shigella flexneri 2a Artificial Invasin Complex (Invaplex\[AR-Detox\]) Vaccine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT01672866

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match SIM via subcutaneous injection every week

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SIM
Description: Subcutaneous injection every week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIM
Description: Subcutaneous injection every week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIM
Description: Subcutaneous injection every week
Study: NCT03155308

Intervention type: DEVICE
Intervention: Pentax chromoendoscopy (i-scan and Optical Enhancement)
Description: All lesions will be evaluated using the 3 i-scan modes and the 2 OE modes without magnification. The lesion size data, location and macroscopic shape of the lesions based on the Paris classification will be recorded. Finally all lesions will be classified in real-time into 3 types based on NICE classification (NICE 1, hyperplastic polyps; NICE 2, adenoma and superficial submucosal carcinoma; NICE 3, SM-d invasive carcinoma). A level of confidence (high or low) will be assign in each stage. Polyp's images will be photographically and videotape recorded. All polyps will be resected or biopsied for histopathological examination used as the criterion standard for the analysis.
Study: NCT00438152

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saquinavir (Invirase®)
Description: Saquinavir 1000mg + Ritonavir 100mg Bd for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir (Kaletra®)
Description: Lopinavir/ritonavir 400/100 mg BD 24 weeks
Study: NCT02190890

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study: NCT01389323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablet, Oral, 60 mg, once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-Interferon Alfa-2a
Description: Syringe, Subcutaneous Injection, 180 μg, Once weekly, 24 or 48 weeks depending on response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet, Oral, 1000 or 1200 mg based on weight, Twice daily, 24 or 48 weeks depending on response
Study: NCT01915823

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azelastine hydrochloride and fluticasone propionate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dymista vehicle
Study: NCT04133714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: multi-channel tDCS
Description: multi-channel transcranial direct current stimulation, tDCS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: multi-channel tDCS
Description: multi-channel transcranial direct current stimulation, tDCS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: single-channel tDCS
Description: single-channel transcranial direct current stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single-channel tDCS
Description: single-channel transcranial direct current stimulation
Study: NCT01020903

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: 40 mg po pre-op

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally, pre-op
Study: NCT04240314

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: scAAV9.U7.ACCA
Description: A single dose of scAAV9.U7.ACCA will be systemically delivered via a peripheral vein injection.
Study: NCT01751776

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 655064
Description: Placebo matching BI 655064 injected subcutaneous.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 655064
Description: Placebo matching BI 655064 injected subcutaneous.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 655064
Description: Placebo matching BI 655064 injected subcutaneous.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655064
Description: BI 655064 injected subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655064
Description: BI 655064 injected subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655064
Description: BI 655064 injected subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655064
Description: BI 655064 injected subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655064
Description: BI 655064 injected subcutaneous
Study: NCT01477008

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiPhasic Cartilage Repair Implant
Description: 1 or 2 BiCRI devices, depending on lesion size

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Marrow Stimulation
Description: Microfracture or Subchondral Drilling
Study: NCT01086540

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: diphenhydramine
Description: Diphenhydramine 50 mg (or equivalent) administered by mouth approximately thirty to sixty minutes prior to each study drug infusion.~Dose may be repeated every four hours, as needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diphenhydramine
Description: Diphenhydramine 50 mg (or equivalent) administered by mouth approximately thirty to sixty minutes prior to each study drug infusion.~Dose may be repeated every four hours, as needed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: acetaminophen
Description: Acetaminophen 650 mg (or equivalent) administered by mouth approximately thirty to sixty minutes prior to each study drug infusion.~Dose may be repeated every four hours, as needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: Acetaminophen 650 mg (or equivalent) administered by mouth approximately thirty to sixty minutes prior to each study drug infusion.~Dose may be repeated every four hours, as needed.
Study: NCT00861991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perspective taking instruction
Description: Students were asked to take the perspective of their standardized patients during clinical skills examinations
Study: NCT03114215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MD1003
Description: capsules 100mg 3 times per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MD1003
Description: capsules 100mg 3 times per day
Study: NCT02348112

Intervention type: DEVICE
Intervention: Transobturator or Retropubic Sling
Description: Both transobturator and retropubic slings are a hammock-like mesh placed underneath the urethra to provide support. A single incision is made in the vaginal wall and two incisions in the abdomen. Tensioning of the sling is achieved by pulling the sling through the abdominal incisions.
Study: NCT00330317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: 2.5mg letrozole once-daily
Study: NCT00914355

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation
Description: Radiation therapy will be delivered on six occasions, over two weeks. Each treatment will take approximately 30 minutes to deliver.You may be asked to swallow 250 cc of oral contrast before each radiation therapy treatment.Pepto Bismol (a liquid that coats the stomach and is used to treat heartburn) and/or water may be combined with the contrast to improve the quality of the stomach's image.
Study: NCT03851042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Head set in PACU
Description: Use of VR headset to determine post op satisfaction in PACU, decreased pain reduction and opioid consumption

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: Routine post laparoscopic hysterectomy management (no VR headset)
Study: NCT03164928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: 1mg/kg BW (up to a maximum of 60 mg) SC Q6M

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: SC Q6M placebo
Study: NCT03043625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visceral manipulation
Description: Participants will be instructed to lie down comfortably on a stretcher in the supine position, with lower limbs flexed and abdomen exposed, and the physiotherapist positioned to the right side of the patient. The therapeutic intervention will be began with the left hand of the physiotherapist in contact with the lower region of the stomach, to which a force will be applied so that the organ was moved in an upper and lateral left direction while the right hand controlled and directed the knees of the patient to the right side until the moment when the physiotherapist notice an increase in tension in the stomach region. For the liver manipulation, the same procedures will be followed, however, with contact in the right epigastric region and the knees directed to the left side. The same position will be maintained for each organ treated until the physiotherapist could feel, through touch, a decrease in the tension of the viscera. The mean treatment time will 5 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group (CG)
Description: The CG will be received placebo treatment. In the placebo treatment, the therapist should place the hands over the navel region without exerting any local tension for 1 minute.